ADA Diabetes Guidelines 2020–2024: Major Changes in Diabetes Care

ADA Diabetes Guidelines 2020–2024: Historical Timeline

The following timeline summarizes important developments in the annual ADA Standards and related consensus publications. The annual Standards and ADA/EASD consensus reports are separate documents, and research published during a year may influence subsequent annual updates.

ADA Diabetes Guidelines 2020: Beyond Glucose Reduction

The 2020 ADA Standards continued the shift toward selecting therapies according to cardiovascular and kidney outcomes, in addition to their glucose-lowering effects.

Evidence from clinical trials published during preceding years had demonstrated that certain SGLT2 inhibitors and GLP-1 receptor agonists could provide benefits beyond lowering A1C in selected populations.

What were the main priorities in 2020?

• Individualizing A1C and glucose targets.
• Considering cardiovascular disease and kidney disease when selecting treatment.
• Managing blood pressure, cholesterol and other risk factors.
• Recognizing hypoglycemia risk.
• Supporting appropriate use of diabetes technology.
• Addressing medication affordability, particularly insulin costs.
• Providing ongoing diabetes self-management education and support.

The recommendations reflected an important principle: lowering glucose is necessary for many aspects of diabetes management, but prevention of long-term complications also requires attention to other clinical outcomes.

Diabetes care during the COVID-19 pandemic

COVID-19 emerged as a major clinical challenge during 2020. People with diabetes were among the populations requiring particular attention to complications and disruptions in care.

Telemedicine and remote glucose monitoring gained practical importance during the pandemic. However, these developments should be distinguished from the ADA Standards first published before the pandemic began.

Source: ADA Summary of Revisions—2020.

ADA Diabetes Guidelines 2021: CGM and Time in Range

The 2021 ADA Standards placed greater explicit emphasis on glucose measures beyond A1C.

A1C remained an important marker of long-term glycemic exposure, but it does not show the full pattern of daily glucose fluctuations, hypoglycemia or variability.

Continuous glucose monitoring can provide additional information about these patterns.

What is time in range?

Time in range (TIR) describes the percentage of monitored time that glucose remains within a specified target range.

For many nonpregnant adults with type 1 or type 2 diabetes, a commonly used reference range is 70–180 mg/dL (3.9–10.0 mmol/L).

The 2021 Standards incorporated time-in-range goals more explicitly within recommendations for glycemic assessment.

For many adults, an illustrative target was more than 70% time in range, but appropriate targets differed by population, health status, pregnancy and hypoglycemia risk.

Expanded CGM recommendations

The 2021 Standards also updated recommendations on CGM use across different insulin treatment approaches and age groups.

These changes reflected the growing role of diabetes technology in reducing hypoglycemia and improving glucose management for appropriate patients.

Original source: ADA Summary of Revisions—2021.

ADA Diabetes Guidelines 2022: A New ADA/EASD Consensus

The 2022 ADA Standards continued developing recommendations for comprehensive diabetes management, including glucose targets, cardiovascular and kidney risk reduction, technology and individualized therapies.

Later in 2022, ADA and the European Association for the Study of Diabetes published a separate joint consensus report titled Management of Hyperglycemia in Type 2 Diabetes, 2022.

This report substantially updated the earlier consensus approach.

What were the major themes in the 2022 consensus?

• Person-centered care: Treatment decisions should reflect individual characteristics, preferences and circumstances.
• Weight management: Weight reduction was emphasized as an important part of treatment for appropriate patients.
• Cardiovascular protection: Medication selection should incorporate evidence from cardiovascular outcome trials.
• Kidney protection: Chronic kidney disease and kidney outcome evidence were central considerations.
• Physical activity: Exercise recommendations included discussion of reducing sedentary time and improving overall activity behaviors.
• Sleep and healthy behaviors: Sleep health and other behavioral factors received greater attention.
• Social determinants of health: Financial access, health systems and individual circumstances were recognized as factors affecting treatment outcomes.

The report emphasized that type 2 diabetes is a complex condition requiring treatment of glucose, weight, cardiovascular risks, comorbidities and overall health.

Did the 2022 consensus replace the ADA Standards?

No. The ADA Standards are updated annually, while the 2022 ADA/EASD consensus was a separately published joint report focused on treatment of hyperglycemia in adults with type 2 diabetes.

It was published online in September 2022 and appeared in the November 2022 issue of Diabetes Care.

Original sources:

• ADA Standards: Summary of Revisions—2022
• 2022 ADA/EASD Consensus Report

ADA Diabetes Guidelines 2023: Weight, Kidney Health and Cardiovascular Risk

The 2023 ADA Standards reflected important advances in understanding how to reduce long-term diabetes complications.

Recommendations increasingly considered therapies with evidence for cardiovascular and kidney protection in appropriately selected patients.

Treatment based on cardiorenal risk

The 2023 Standards reinforced the importance of selecting medications that could reduce cardiovascular and kidney risks in adults with type 2 diabetes and relevant conditions.

Depending on the clinical setting and the available evidence, options included certain SGLT2 inhibitors, GLP-1 receptor agonists and other therapies.

These recommendations were specific to patients' diagnoses, kidney function, cardiovascular conditions and treatment safety.

Obesity and weight management

The 2023 Standards gave additional attention to weight management in type 2 diabetes.

They discussed the potential for larger weight reductions to improve metabolic outcomes and, in certain circumstances, contribute to diabetes remission.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, was included among glucose-lowering treatment options with significant weight-loss potential.

These developments reflected a shift toward treating excess adiposity as a major component of metabolic disease management when clinically appropriate.

Other important changes in 2023

• Revised blood pressure recommendations for people with diabetes.
• Updated LDL cholesterol treatment targets for selected cardiovascular-risk groups.
• Additional guidance for heart failure and chronic kidney disease.
• Updates to continuous glucose monitoring and insulin-delivery technology.
• Greater emphasis on diabetes distress, psychosocial care and sleep health.
• Additional discussion of liver disease and fibrosis risk assessment.
• Recommendations concerning treatment simplification and hypoglycemia prevention in older adults.

Some 2023 recommendations were specifically intended for high-risk populations and should not be interpreted as universal treatment instructions.

Source: ADA Summary of Revisions—2023.

ADA Diabetes Guidelines 2024: Expanding Personalized Diabetes Care

The 2024 ADA Standards continued refining comprehensive care across glucose management, cardiovascular risk, kidney disease, obesity, diabetes technology and chronic complication prevention.

The annual update included additional attention to equitable care, patient preferences, treatment burden and the affordability of medicines and monitoring devices.

Weight-management treatment in 2024

One important development was the greater prominence of modern obesity pharmacotherapy in diabetes management.

The 2024 ADA Standards recommended considering obesity pharmacotherapy for people with diabetes and overweight or obesity when appropriate, alongside lifestyle intervention and careful assessment of risks and benefits.

In relevant patients, the guidance highlighted therapies with greater weight-loss efficacy, including semaglutide and tirzepatide.

These recommendations did not mean that every person with diabetes should receive an obesity medication. Patient eligibility, medical history, adverse effects, treatment goals and access remained important.

Glucose monitoring and diabetes technology

By 2024, recommendations on CGM, automated insulin delivery and glucose-management technology had advanced considerably from those available in 2000.

Technology was increasingly recognized as a component of diabetes care for suitable patients, but effective use still required education, clinical support and reliable access to supplies.

Comprehensive prevention of complications

The 2024 Standards also continued updating recommendations across:

• Cardiovascular disease and blood pressure management.
• Chronic kidney disease evaluation and treatment.
• Retinopathy, neuropathy and foot health.
• Nutrition, physical activity and weight management.
• Diabetes care in older adults.
• Diabetes care during pregnancy.
• Care in children, adolescents and hospitalized patients.

The overall direction was toward increasingly individualized treatment based on both clinical evidence and patient circumstances.

Original sources:

• ADA Summary of Revisions—2024
• Obesity and Weight Management: ADA Standards—2024

How Diabetes Monitoring Changed Between 2020 and 2024

During this period, CGM and related technologies became increasingly integrated into clinical recommendations.

A1C remained useful, but it cannot reveal all daily glucose fluctuations.

The historical advance was the increasing use of complementary glucose measures rather than reliance on a single number.

Why Heart and Kidney Protection Became Central to Diabetes Care

In the early 2000s, cardiovascular risk management was already an important component of ADA guidance.

By 2020–2024, however, clinical trials had provided more detailed evidence about the cardiovascular and kidney effects of specific glucose-lowering medications.

This supported a more targeted treatment approach for patients with:

• Established atherosclerotic cardiovascular disease.
• Heart failure.
• Chronic kidney disease.
• Elevated cardiovascular or kidney risk.

Medication selection increasingly considered these conditions alongside A1C, weight, adverse effects and patient preferences.

It is important to distinguish proven drug-specific outcomes from broad claims that all members of a medication class provide identical benefits.

Why Weight Management Became More Prominent

Weight management has long been an important part of diabetes prevention and treatment.

During 2020–2024, newer pharmacological evidence supported a more prominent role for weight management in selected people with type 2 diabetes.

The 2022 ADA/EASD consensus and subsequent ADA Standards increasingly treated weight as an important clinical outcome alongside glucose management.

For appropriate patients, available approaches included:

• Individualized nutrition therapy.
• Regular physical activity and resistance exercise.
• Behavioral support and sustainable lifestyle changes.
• Weight-reducing medications when indicated.
• Metabolic surgery for eligible patients.

The emphasis was not on appearance or a universal body-weight target. Rather, the goal was to improve health outcomes through an evidence-based, individualized treatment plan.

How 2020–2024 Recommendations Compare With Current Diabetes Care

The 2020–2024 Standards laid important foundations for contemporary diabetes management, particularly in technology, cardiovascular and kidney risk reduction, and obesity treatment.

However, the historical documents should not be treated as identical to the most recent ADA Standards.

• Clinical trials published after 2024 may change how treatments are selected.
• Medication indications, contraindications and regulatory approvals can change.
• Diabetes technologies continue to evolve.
• Guideline recommendations may be updated when new evidence becomes available.
• Individual treatment always requires consideration of the patient's health status and preferences.

Medical information notice: This independently authored article is intended for historical education and is not an official publication of the American Diabetes Association or EASD. Historical recommendations must not replace current medical advice, diagnosis or treatment. Do not change diabetes medication or insulin doses based on this article.